Dr. Kalinsky on Clinical Impact of Atezolizumab Combo in TNBC

Kevin Kalinsky, MD, MS, discusses the clinical impact of the combination of atezolizumab and nab-paclitaxel in triple-negative breast cancer. Website: https://www.onclive.com Twitter: / onclive Facebook: / onclive LinkedIn: / onclive

Dr. Kalinsky on Clinical Impact of Atezolizumab Combo in TNBC

Kevin Kalinsky, MD | Advances in Breast Cancers at 2019 ASCO Direct Highlights Philadelphia

ESMO 2020 Expert Video report on atezolizumab in upfront treatment of TNBC

NeoTRIP: EFS in neoadjuvant atezolizumab with taxane/carboplatin ± anthracycline in high-risk TNBC

Copy of Dr. Hamilton on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBC

Kevin Kalinsky, MD | Key Takeaways on Breast Cancers at 2019 ASCO Direct Highlights Philadelphia

Dr. Kalinsky on CNS Involvement in HER2+ Breast Cancer

Dr. Tolaney on Pembrolizumab Plus Eribulin in TNBC

Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBC

Assessing the impact of atezolizumab in NSCLC

Early TNBC - Pembrolizumab + chemotherapy: Pathologic complete response in key subgroups

Combination therapy IO + Chemo in Triple Negative Breast Cancer Schmid 2

Dr. Eric Winer on Carboplatin and/or Bevacizumab in Triple-Negative Breast Cancer

Atezolizumab Final Presentation

The evolution of immunotherapy for breast cancer

How do side effects from immunotherapy differ from side effects from chemotherapy in lung cancer?

Dr. White on CNS Metastases in HER2+ Breast Cancer

HER2CLIMB Study Shows Efficacy in HER2 Breast Cancer With Brain Metastases

Corona Virus in New York. April 6, 2020